BRPI1012845A2 - peptideos derivados de fviii. - Google Patents

peptideos derivados de fviii.

Info

Publication number
BRPI1012845A2
BRPI1012845A2 BRPI1012845A BRPI1012845A BRPI1012845A2 BR PI1012845 A2 BRPI1012845 A2 BR PI1012845A2 BR PI1012845 A BRPI1012845 A BR PI1012845A BR PI1012845 A BRPI1012845 A BR PI1012845A BR PI1012845 A2 BRPI1012845 A2 BR PI1012845A2
Authority
BR
Brazil
Prior art keywords
fviii
present
peptides derived
peptide
provides
Prior art date
Application number
BRPI1012845A
Other languages
English (en)
Portuguese (pt)
Inventor
David Wraith
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1012845(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of BRPI1012845A2 publication Critical patent/BRPI1012845A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1012845A 2009-05-18 2010-05-17 peptideos derivados de fviii. BRPI1012845A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0908515.0A GB0908515D0 (en) 2009-05-18 2009-05-18 Peptide
PCT/GB2010/000997 WO2010133834A2 (en) 2009-05-18 2010-05-17 Peptide

Publications (1)

Publication Number Publication Date
BRPI1012845A2 true BRPI1012845A2 (pt) 2016-10-11

Family

ID=40834163

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012845A BRPI1012845A2 (pt) 2009-05-18 2010-05-17 peptideos derivados de fviii.

Country Status (30)

Country Link
US (1) US8703705B2 (enExample)
EP (2) EP2465523B1 (enExample)
JP (1) JP5784009B2 (enExample)
KR (1) KR101673889B1 (enExample)
CN (1) CN102458445B (enExample)
AU (1) AU2010250957B2 (enExample)
BR (1) BRPI1012845A2 (enExample)
CA (1) CA2762020C (enExample)
CL (1) CL2011002893A1 (enExample)
CO (1) CO6460780A2 (enExample)
CY (1) CY1115832T1 (enExample)
DK (1) DK2465523T3 (enExample)
EA (1) EA027229B1 (enExample)
EC (1) ECSP11011540A (enExample)
ES (1) ES2525448T3 (enExample)
GB (1) GB0908515D0 (enExample)
HR (1) HRP20141182T1 (enExample)
IL (1) IL216199A (enExample)
MX (1) MX2011012270A (enExample)
MY (1) MY168207A (enExample)
NZ (2) NZ613713A (enExample)
PL (1) PL2465523T3 (enExample)
PT (1) PT2465523E (enExample)
RS (1) RS53671B1 (enExample)
SG (2) SG190573A1 (enExample)
SI (1) SI2465523T1 (enExample)
SM (1) SMT201400186B (enExample)
UA (1) UA110921C2 (enExample)
WO (1) WO2010133834A2 (enExample)
ZA (1) ZA201108446B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353233B (es) 2009-12-06 2018-01-08 Bioverativ Therapeutics Inc Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos.
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
GB201314052D0 (en) * 2013-08-06 2013-09-18 Apitope Int Nv Peptides
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US20040096456A1 (en) * 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP2005538694A (ja) * 2002-04-18 2005-12-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 修飾されたviii因子
GB0723712D0 (en) * 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII

Also Published As

Publication number Publication date
KR101673889B1 (ko) 2016-11-08
SMT201400186B (it) 2015-01-15
GB0908515D0 (en) 2009-06-24
CA2762020A1 (en) 2010-11-25
CA2762020C (en) 2018-08-28
CN102458445B (zh) 2014-06-11
SI2465523T1 (sl) 2015-02-27
IL216199A0 (en) 2012-01-31
MX2011012270A (es) 2011-12-12
KR20120023023A (ko) 2012-03-12
WO2010133834A3 (en) 2011-02-24
WO2010133834A2 (en) 2010-11-25
US20120121625A1 (en) 2012-05-17
EP2465523B1 (en) 2014-10-01
CL2011002893A1 (es) 2012-08-17
JP5784009B2 (ja) 2015-09-24
HK1173358A1 (en) 2013-05-16
SG176138A1 (en) 2011-12-29
EP2432494A2 (en) 2012-03-28
JP2012527440A (ja) 2012-11-08
HRP20141182T1 (hr) 2015-02-13
DK2465523T3 (en) 2014-12-15
NZ613713A (en) 2014-10-31
PT2465523E (pt) 2014-12-09
SG190573A1 (en) 2013-06-28
US8703705B2 (en) 2014-04-22
NZ596300A (en) 2013-08-30
UA110921C2 (uk) 2016-03-10
EA201171430A1 (ru) 2012-05-30
CO6460780A2 (es) 2012-06-15
AU2010250957A1 (en) 2011-12-01
EP2465523A1 (en) 2012-06-20
RS53671B1 (sr) 2015-04-30
ECSP11011540A (es) 2012-01-31
AU2010250957B2 (en) 2015-01-15
ES2525448T3 (es) 2014-12-23
IL216199A (en) 2015-11-30
EA027229B1 (ru) 2017-07-31
PL2465523T3 (pl) 2015-03-31
CY1115832T1 (el) 2017-01-25
ZA201108446B (en) 2013-01-30
CN102458445A (zh) 2012-05-16
MY168207A (en) 2018-10-15

Similar Documents

Publication Publication Date Title
BRPI1012845A2 (pt) peptideos derivados de fviii.
BR122021020829B8 (pt) Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
CY1121560T1 (el) Ανοσογονικη συνθεση
BR112012019693A2 (pt) anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
ECSP11010812A (es) Complejo de mineral-aminoácido polisacárido
MX2011013455A (es) Diseño de moleculas de fc de anticuerpo estables y libres de agregacion a traves del diseño de la interfase del dominio de ch3.
EA200870237A1 (ru) Последовательности пептидов и композиции
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
EP4296673A3 (en) Peptides and methods for the detection of lyme disease antibodies
IN2014DN10288A (enExample)
MY150995A (en) Fviii peptides and their use in tolerising haemophiliacs
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
BR112015010625A2 (pt) Peptídeos
CA2863661C (en) Diagnostic peptides for lyme disease
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
WO2013085897A3 (en) A method for reducing agglomeration in gypsum plaster or filling compositions comprising cellulose ether
FR2911608B1 (fr) Nouvelles compositions vaccinales anti paludique et ses utilisations.
BR112012013581A2 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhante a ferlinas e outras proteínas que contêm o domínio c2
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
MY166516A (en) Tomm34 peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
WO2011161545A3 (en) Non-hydrolyzable protein conjugates, methods and compositions related thereto
WO2013104918A3 (en) Binding molecule
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
TW200730192A (en) Compositions for separation of a plurality of distinct targets from a sample

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: APITOPE INTERNATIONAL NV (BE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2567 DE 2020-03-17

B350 Update of information on the portal [chapter 15.35 patent gazette]